Clinical Trials for Squamous Cell Carcinoma Of The Skin

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, advanced unresectable or metastatic solid tumors and no suitable curative treatment receive intratumoral or intravenous VET3-TGI, alone or with pembrolizumab. VET3-TGI is an oncolytic vaccinia virus engineered to express CXCR3 and IL-12 and inhibit TGF-β to promote tumor killing and antitumor immunity.

ClinicalTrials.gov ID: NCT06444815

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with measurable, unresectable locally advanced or metastatic epithelial carcinomas that have relapsed or are refractory after at least two prior treatment lines, have no standard options, and have ECOG performance status 0–1 receive DR-0202 every two weeks. DR-0202 is an investigational bispecific antibody designed to bring myeloid immune cells into contact with tumor cells; its tumor-cell target has not been disclosed.

ClinicalTrials.gov ID: NCT06999187

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with PIK3CA-mutated, unresectable or metastatic solid tumors after at least one prior therapy receive oral ETX-636, an investigational mutant-selective PI3Kα inhibitor, as monotherapy. Patients with HR-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor and anti-estrogen therapy may receive ETX-636 plus fulvestrant.

ClinicalTrials.gov ID: NCT06993844

GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic TP53 R175H-mutant solid tumors who are HLA-A*02:01-positive and have exhausted standard options receive CLSP-1025 monotherapy. This investigational T-cell engager binds CD3 and an HLA-A*02:01-presented mutant p53 peptide to direct T-cell killing of tumor cells.

ClinicalTrials.gov ID: NCT06778863

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors and ECOG performance status 0–1 receive intravenous TUB-030 every three weeks; dose-optimization cohorts are limited to NSCLC and HNSCC. TUB-030 is an investigational 5T4-targeting antibody–drug conjugate that delivers exatecan, a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06657222

Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic melanoma (including prior brain metastases) or other relapsed/refractory, IL13Ralpha2-expressing solid tumors to receive lymphodepleting chemotherapy followed by systemic infusion of autologous CAR T cells targeting IL13Ralpha2, a tumor-associated antigen. Patients must have good performance status and tumors confirmed to express IL13Ralpha2 by immunohistochemistry.

ClinicalTrials.gov ID: NCT04119024

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors refractory to standard therapy or lacking a standard option, and ECOG performance status 0–1, receive IV LCB84 alone or with an anti-PD-1 antibody; expansion cohorts focus on selected tumor types. LCB84 is a TROP2-directed antibody–drug conjugate that delivers the cytotoxic payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT05941507

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring selected MAPK-pathway mutations, ECOG 0–1, and no suitable standard therapy receive oral IPN01194 monotherapy. IPN01194 inhibits ERK1/2, downstream components of MAPK signaling.

ClinicalTrials.gov ID: NCT06305247

Phase I Trial of Radiotherapy in Combination With Atezolizumab in Borderline Resectable and Unresectable Cutaneous Squamous Cell Carcinoma(cSCC)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with borderline resectable or unresectable cutaneous SCC (including oligometastatic disease, 1–3 sites) receive SBRT to the primary/target lesion followed by atezolizumab, a PD‑L1–blocking monoclonal antibody, given every 21 days for up to 3 cycles. Excludes prior PD‑1/PD‑L1/CTLA‑4 therapy and active autoimmune or infectious contraindications; aims to assess safety and preliminary efficacy of the SBRT–immunotherapy combination.

ClinicalTrials.gov ID: NCT05085496

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.

ClinicalTrials.gov ID: NCT07189871